--- title: "Eikon Therapeutics (EIKN) news: IPO and offering" url: "https://aibio.space/companies/eikon-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "EIKN IPO and offering news: Eikon Therapeutics prices IPO of 21,177,600 shares at $18.00. Eikon Therapeutics, Inc. (NASDAQ: EIKN), United States." --- EIKN Eikon Therapeutics, Inc. NASDAQ · United States # Eikon Therapeutics (EIKN) news EIKN IPO and offering news Financings · 2026-02-05 ## [Eikon Therapeutics prices IPO of 21,177,600 shares at $18.00](https://aibio.space/news/eikon-therapeutics-prices-ipo-21-177-600-shares-18-00/) The offering totals $381,196,800. The stock is approved to list on Nasdaq under EIKN, and proceeds to the company are $354,513,024 before expenses. ## Latest Eikon Therapeutics news 1. 2026-01-09 Financings [Eikon Therapeutics files for IPO of common stock, seeks Nasdaq listing as EIKN](https://aibio.space/news/eikon-therapeutics-files-ipo-common-stock-seeks-nasdaq-listing-eikn/) The Delaware company applied to list on the Nasdaq Global Market. The share count and price range are blank in the preliminary prospectus. ## Eikon Therapeutics at a glance - **Ticker**: EIKN - **Listing**: NASDAQ - **Country**: United States ### Related companies - [Palisade Bio](https://aibio.space/companies/palisade-bio/) NASDAQ: PALI - [Compass Therapeutics](https://aibio.space/companies/compass-therapeutics/) NASDAQ: CMPX - [Bioxytran](https://aibio.space/companies/bioxytran/) OTC: BIXT - [Rafarma Pharmaceuticals, Inc. (WY)](https://aibio.space/companies/rafarma-pharmaceuticals-wy/) OTC: RAFA - [AEON Biopharma](https://aibio.space/companies/aeon-biopharma/) AMEX: AEON - [Niki BioSolutions](https://aibio.space/companies/niki-biosolutions/) NASDAQ: NIKI - [Harrow](https://aibio.space/companies/harrow/) NASDAQ: HROW - [Annexon](https://aibio.space/companies/annexon/) NASDAQ: ANNX ### Also on NASDAQ - [Scilex Holding](https://aibio.space/companies/scilex/) SCLX - [MoonLake Immunotherapeutics](https://aibio.space/companies/moonlake-immunotherapeutics/) MLTX - [Prenetics Global](https://aibio.space/companies/prenetics-global/) PRE - [Apnimed](https://aibio.space/companies/apnimed/) APMD - [Xencor](https://aibio.space/companies/xencor/) XNCR - [Neuphoria Therapeutics](https://aibio.space/companies/neuphoria-therapeutics/) NEUP ## Questions about Eikon Therapeutics When did Eikon Therapeutics go public? Our latest story on this, dated Feb 5, 2026: "Eikon Therapeutics prices IPO of 21,177,600 shares at $18.00". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/eikon-therapeutics-prices-ipo-21-177-600-shares-18-00/). Has Eikon Therapeutics raised money recently? Our latest story on this, dated Feb 5, 2026: "Eikon Therapeutics prices IPO of 21,177,600 shares at $18.00". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/eikon-therapeutics-prices-ipo-21-177-600-shares-18-00/). What is the ticker symbol of Eikon Therapeutics? Eikon Therapeutics, Inc. trades under the ticker EIKN on NASDAQ. Where is Eikon Therapeutics listed? Eikon Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Eikon Therapeutics? The SEC Central Index Key (CIK) for Eikon Therapeutics, Inc. is 1861123. Its filings are on SEC EDGAR. How many shares does Eikon Therapeutics have outstanding? 54,165,030 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Eikon Therapeutics listed under? Our directory records Eikon Therapeutics, Inc. under United States. What does Eikon Therapeutics do? Our directory classifies Eikon Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Eikon Therapeutics? The ISIN recorded for Eikon Therapeutics, Inc. is US2825641036. Does aibio.space cover Eikon Therapeutics? aibio.space lists Eikon Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Eikon Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What is the latest Eikon Therapeutics (EIKN) stock news? Our latest story on Eikon Therapeutics, dated Feb 5, 2026: "Eikon Therapeutics prices IPO of 21,177,600 shares at $18.00". The offering totals $381,196,800. The stock is approved to list on Nasdaq under EIKN, and proceeds to the company are $354,513,024 before expenses. [Source](https://aibio.space/news/eikon-therapeutics-prices-ipo-21-177-600-shares-18-00/). How long will Eikon Therapeutics's cash last? From our story of Feb 5, 2026: The prospectus says its recurring losses and financial condition raise substantial doubt about its ability to continue as a going concern. [Source](https://aibio.space/news/eikon-therapeutics-prices-ipo-21-177-600-shares-18-00/). Is Eikon Therapeutics a smaller reporting company? SEC records list Eikon Therapeutics, Inc.'s filer category as:
Emerging growth company. Where is Eikon Therapeutics headquartered? SEC records list its business address as 230 HARRIET TUBMAN WAY, MILLBRAE, CA, 94030. ## Investor discussion: Eikon Therapeutics Members talk about Eikon Therapeutics (EIKN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Eikon Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-02-05 Financings Filed a final prospectus for a securities offering. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1861123/000119312526039375/d99350d424b4.htm) 2. 2026-01-09 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1861123/000119312526008888/d903262ds1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:EIKN on TradingView](https://www.tradingview.com/symbols/NASDAQ-EIKN/). ## SEC filings and registration - **SEC name**: Eikon Therapeutics, Inc. - **CIK**: 1861123 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: EIKN (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 230 HARRIET TUBMAN WAY, MILLBRAE, CA, 94030 - **Phone**: 341-777-0566 - **Shares outstanding**: 54,165,030 as of 2026-08-03 (10-Q filed 2026-08-13) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1861123/000119312526349936/eikn-20260813.htm) filed 2026-08-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/1861123/000119312526349185/eikn-20260630.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1861123/000119312526349154/eikn-20260813.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1861123/000119312526330710/eikn-20260731.htm) filed 2026-08-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1861123/000119312526265861/eikn-20260605.htm) filed 2026-06-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1861123/000119312526249725/eikn-20260530.htm) filed 2026-06-01 - [10-Q](https://www.sec.gov/Archives/edgar/data/1861123/000119312526216791/eikn-20260331.htm) filed 2026-05-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1861123/000119312526216744/eikn-20260511.htm) filed 2026-05-11 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001861123), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Eikon Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker EIKN, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Eikon Therapeutics, Inc. - **Ticker**: EIKN - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US2825641036 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-EIKN/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/eikon-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Eikon Therapeutics (EIKN) news: IPO and offering", 2026-10-31, https://aibio.space/companies/eikon-therapeutics/